Engineered immune cells and vaccine take on Hard-to-Treat cancers

This early-phase trial tests a treatment for adults with metastatic solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. Doctors take a person's own white blood cells, modify them in a lab to better recognize and attack cancer cells, and return them to the patient along with a vaccine to boost their effect. The goal is to see if this combination can shrink tumors and is safe. Participants receive chemotherapy before the cell infusion and stay in the hospital for 3-4 weeks.